Snowden Capital Advisors’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Snowden Capital Advisors’s Portfolio GNOM Stock Details GNOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,313	Closed	-$104K	–	1455
2021 Q4	$104K	Buy	+1,313	New	+$110K	0.01%	828

Other funds holding GNOM

PAG

Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

MIG

McGuire Investment Group Wakefield, Rhode Island $885M AUM 47.78% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

OCM

One Capital Management Westlake Village, California $3.65B AUM 15.32% 1-Year Est. Return

MML Investors Services Springfield, Massachusetts $36.1B AUM 19.68% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

EWM

Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return

Snowden Capital Advisors's GNOM Position: Q1 2022 in Review

Snowden Capital Advisors sold out of Global X Genomics & Biotechnology ETF (GNOM) in Q1 2022, closing a stake of 1,313 shares — an estimated $104K sold.

Snowden Capital Advisors first reported a position in GNOM in Q4 2021 and held it in 1 quarter. The position peaked at $104K in Q4 2021. 60 funds tracked by Wall St. Rank hold GNOM as of Q1 2022.

Snowden Capital Advisors reported no remaining Global X Genomics & Biotechnology ETF position as of Q1 2022 after selling out during the quarter.
Snowden Capital Advisors sold 1,313 Global X Genomics & Biotechnology ETF shares in Q1 2022, an estimated $104K.
Snowden Capital Advisors first reported a position in Global X Genomics & Biotechnology ETF in Q4 2021 and held it in 1 quarter.
Snowden Capital Advisors's Global X Genomics & Biotechnology ETF position peaked at $104K in Q4 2021.
60 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q1 2022.

Based on Snowden Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.